Stay Ahead of Compliance with Monthly Citation Updates


In your State Survey window and need a snapshot of your risks?

Survey Preparedness Report

One Time Fee
$79
  • Last 12 months of citation data in one tailored report
  • Pinpoint the tags driving penalties in facilities like yours
  • Jump to regulations and pathways used by surveyors
  • Access to your report within 2 hours of purchase
  • Easily share it with your team - no registration needed
Get Your Report Now →

Monthly citation updates straight to your inbox for ongoing preparation?

Monthly Citation Reports

$18.90 per month
  • Latest citation updates delivered monthly to your email
  • Citations organized by compliance areas
  • Shared automatically with your team, by area
  • Customizable for your state(s) of interest
  • Direct links to CMS documentation relevant parts
Learn more →

Save Hours of Work with AI-Powered Plan of Correction Writer


One-Time Fee

$49 per Plan of Correction
Volume discounts available – save up to 20%
  • Quickly search for approved POC from other facilities
  • Instant access
  • Intuitive interface
  • No recurring fees
  • Save hours of work
F0580
D

Failure to Notify Resident Representative of Significant Medication Change

Rochester, New York Survey Completed on 08-20-2025

Penalty

No penalty information released
tooltip icon
The penalty, as released by CMS, applies to the entire inspection this citation is part of, covering all citations and f-tags issued, not just this specific f-tag. For the complete original report, please refer to the 'Details' section.

Summary

The facility failed to immediately notify a resident's representative when there was a significant change in the resident's treatment plan. Specifically, a resident with diagnoses including acute embolism, thrombosis of the right femoral vein, vascular dementia, and a history of cerebral infarction was prescribed Lovenox injections for deep vein thrombosis. The resident, who had severely impaired cognition, refused the Lovenox on several occasions, leading to the medication being discontinued by a provider. Despite facility policy requiring notification of the resident's representative in such cases, there was no documented evidence that the representative was informed of either the refusals or the discontinuation of the medication. Further review of the resident's records showed that after the medication was discontinued, the resident experienced a medical event and was transported to the hospital, where they were diagnosed with an acute ischemic stroke. During the hospital admission, the resident's representative reported being unsure if the resident had been receiving the Lovenox injections at the facility. Interviews confirmed that the provider should have notified the representative about the medication change, but this did not occur.

An unhandled error has occurred. Reload 🗙